3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
52
Thoracic
4
Gynecologic
4
Breast
4
Head & Neck
3
Dermatologic
3
Sarcoma
2
Lymphoid
2
Genitourinary
2
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Endocrine
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
32
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Leukemia
16
Lymphoma, Non-Hodgkin
9
Lymphoma
9
Leukemia, Lymphocytic, Chronic, B-Cell
8
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma, Mantle-Cell
6
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma, Follicular
5
Burkitt Lymphoma
5
Recurrence
4
Neoplasms
4
Myelodysplastic Syndromes
4
Lymphoma, Large-Cell, Anaplastic
4
Congenital Abnormalities
4
Anemia, Refractory, with Excess of Blasts
4
Waldenstrom Macroglobulinemia
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Myeloproliferative Disorders
3
Multiple Myeloma
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Extranodal NK-T-Cell
3
Leukemia, Myelomonocytic, Juvenile
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Immunoblastic Lymphadenopathy
3
Hematologic Neoplasms
3
Thrombocythemia, Essential
2
Sezary Syndrome
2
Primary Myelofibrosis
2
Interventions
Specimen Handling
2
Polymerase Chain Reaction
2
Magnetic Resonance Spectroscopy
2
Gene Expression Profiling
2
Counseling
2
Bupropion
2
vactosertib
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
temsirolimus
1
tanespimycin
1
sapanisertib
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
fludarabine phosphate
1
erdafitinib
1
entinostat
1
defactinib
1
dabrafenib
1
copanlisib
1
capmatinib
1
capivasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Drug Therapy
×
Other hematologic neoplasm
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled